CONTACT

Laurent BARTHOLIN
Chef d'équipe
laurent.bartholin@lyon.unicancer.fr
04 78 78 28 63

Cheney A - 5ème étage
Centre Léon Bérard

Statutaires
Laurent Bartholin,
CR1 INSERM, PhD
laurent.bartholin@lyon.unicancer.fr

Philippe Cassier, Praticien hospitalier CLB, MD-PhD
philippe.cassier@lyon.unicancer.fr

Clélia Coutzac, Praticien hospitalier CLB,MD-PhD,
Clelia.COUTZAC@lyon.unicancer.fr

Christelle de la Fouchardière, Praticien hospitalier CLB, MD
christelle.delafourchardière@lyon.unicancer.fr

Isabelle Goddard, Ingénieur de Recherche CNRS, PhD,
isabelle.goddard@lyon.unicancer.fr

Stéphanie Sentis, MCU ISPB-UCBL, PhD
stephanie.sentis@lyon.unicancer.fr

Sylvie Martel, Technicienne CLB
sylvie.martel@lyon.unicancer.fr

Sophie Aires, Assistante-Ingénieur UCBL
sophie.aires@univ-lyon1.fr

Doctorants
Adrien Bertrand,
doctorant
adrien.bertrans@lyon.unicancer.fr

Veronique Chauvet, doctorante
veronique.chauvet@lyon.unicancer.fr

Post-Doc
Cassandre Caligaris,
post-doctorante, PhD
cassandre.caligaris@lyon.unicancer.fr

Voir les objectifs et projets Voir les publications
Financements 
INSERM Programme Avenir
Ligue nationale contre le cancer
Fondation ARC
INCa (Institut National du Cancer)

OBJECTIFS

L’objectif de nos travaux vise à comprendre les mécanismes cellulaires et moléculaires impliqués dans l’adénocarcinome du pancréas, une tumeur agressive qui représente la cinquième cause de mortalité par cancer. La finalité de nos travaux est de développer de nouvelles stratégies thérapeutiques contre cette tumeur. Dans ce contexte, nous nous intéressons tout particulièrement au rôle du Transforming Growth Factor Beta (TGFβ), la totalité des adénocarcinomes du pancréas présentant des altérations génétiques ou épigénétiques affectant la voie de signalisation du TGFβ. Le TGFβ peut agir comme un « suppresseur de tumeur » ou un « oncogène » suivant le type de tumeur, son stade et son grade. Une meilleure compréhension des bases moléculaires de cette dualité fonctionnelle devrait permettre de développer des traitements innovants contre l’adénocarcinome du pancréas en ciblant spécifiquement les effets oncogéniques du TGFβ.

PROJETS

Nous nous intéressons dans l’équipe à l’adénocarcinome du pancréas, une tumeur agressive et résistante à la plupart des traitements actuels. Le cancer du pancréas représente la 5ème cause de mortalité par cancer avec une survie à trois ans d’environ 5%. Il constitue donc un véritable enjeu de santé publique, d’autant plus que son incidence augmente avec l’allongement de l’espérance de vie. Dans ce contexte, il est crucial de développer et proposer aux patients des traitements plus efficaces.

Nous nous intéresserons particulièrement au TGFβ (Transforming Growth Factor Beta), une cytokine jouant un rôle crucial dans la tumorigenèse pancréatique puisque sa signalisation est affectée dans la totalité des adénocarcinomes du pancréas. La voie du TGFβ constitue donc une potentielle cible thérapeutique attractive.

Nos travaux de recherche se caractérisent par un continuum, des aspects les plus fondamentaux impliqués dans les différentes étapes de la transformation tumorale (initiation, progression et dissémination des tumeurs) jusqu’à la mise en place d’études précliniques pour tester de nouvelles approches thérapeutiques. Nous recherchons également des marqueurs précoces de la maladie (puisqu’elle est généralement détectée trop tardivement) et des marqueurs pronostiques (permettant d’anticiper une éventuelle résistance aux traitements).

Vers la page web de l'équipe: cliquez ici

PUBLICATIONS

Publications originales

Cardot-Ruffino V., Chauvet V., Caligaris C., Bertrand-Chapel A., Chuvin N., Pommier R.M., Valcourt U., Vincent D., Martel S., Aires S., Kaniewski B., Dubus P., Cassier,P., Sentis S., Bartholin L. Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strain. Genesis 2020 (in Press)

 

Cardot-Ruffino V., Chauvet V., Caligaris C., Bertrand-Chapel A., Chuvin N., Pommier R.M., Valcourt U., Vincent D., Martel S., Aires S., Kaniewsk, B., Dubus P., Cassier P., Sentis S., Bartholin L. Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblasts. Sci Rep. 2020 Mar 3;10(1):3880. doi: 10.1038/s41598-020-60272-3.

Roger E, Martel S, Bertrand-Chapel A, Depollier A, Chuvin N, Pommier RM, Yacoub K, Caligaris C, Cardot-Ruffino V, chauvet V, aires S, Mohkam K, Mabrut JY, Adham M, Fenouil T, Hervieu V, Broutier L, Castets M, Neuzillet C, Cassier PA, Tomasini R, Sentis S, Bartholin L. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Cell Death Dis. 2019; 10(12):886

Chuvin N., Vincent D.F., Pommier R.M., Alcaraz L.B., Gout J., Yacoub K., Caligaris C., Cardot V., Roger E., Kaniewski B., Martel S., …, Valcourt U., Sentis S., ..., Bartholin L. Acinar-to-Ductal Metaplasia Induced by TGFβ Facilitates KrasG12D-driven Pancreatic Tumorigenesis. Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):263-282. doi: 10.1016/j.jcmgh.2017.05.005. eCollection 2017 Sep.

Valcourt U., Alcaraz L.B., Exposito J.Y., Lethias C., Bartholin L. Tenascin-X: beyond the architectural function. 2015. Cell. Adh. Migr.;9(1-2):154-65. Review.

Pommier R.M., Gout J., Vincent D.F., Alcaraz L.B., Chuvin N., Arfi V., Martel S., Kaniewski B., Devailly G., Fourel G., Bernard P., Moyret-Lalle C., Ansieau S., Puisieux A., Valcourt U., Sentis S., Bartholin L. TIF1-γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability. Cancer Res. 2015 Oct 15;75(20):4335-50.

Alcaraz L.B., Exposito J.Y., Chuvin N., Pommier R.M., Cluzel-Grangeasse C., Martel S., Sentis S., Bartholin L.*, Lethias C.*, Valcourt U.*. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGFβ. J. Cell. Biol. 2014 May 12;205(3):409-28. *These authors have equally contributed to this work. 

Gout J, Pommier RM, Vincent DF, Ripoche G, Goddard-Léon S, Colombe A, Treilleux I, Valcourt U, Tomasini R, Dufresne M, Bertolino P, Bartholin L. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions. Pancreatology. 2013; 13(3): 191-5

Wiel C., Augert A., Vincent D.F., Gitenay D., Vindrieux D., Le Calvé B., Arfi V., Lallet-Daher H., Reynaud C., Treilleux I., Bartholin L., Lelievre E., Bernard D. Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis., Oct 10;4:e855, 2013

Cano C.E., Hamidi T., Garcia M.N., Grasso D., Loncle C, Garcia S., Calvo E., Lomberk G., Dusetti N., Bartholin L., Urrutia R., Iovanna J.L. Genetic Inactivation of Nupr1 acts as a dominant suppressor event in a two Hit Model of pancreatic carcinogenesis. Gut, Sep 14. doi: 10.1136/gutjnl-2013-30522, 2013

Gout J., Pommier R.M., Vincent D.F., Kaniewski B., Martel S., Valcourt U., Bartholin L. Isolation and culture of mouse primary pancreatic acinar cells. J. Vis. Exp., (78): e50514, 2013

Gout J., Pommier R.M., Vincent D.F., Ripoche D., Goddard-Leon S., Colombe A., Treilleux I., Valcourt U., Tomasini R., Dufresne M., Bertolino P., Bartholin L. The conditional expression of KRASG12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions. Pancreatology 13(3): 191-195, 2013

Ripoche D., Gout J., Pommier R.M., Jaafar R., Zhang C.X., Bartholin L., Bertolino P. Generation of a conditional mouse model to inactivate Acvr1b in adult tissues. Genesis 51(2): 120-127, 2013

Cano C.E., Sandí M.J., Hamidi T., Calvo E.L., Turrini O., Bartholin L., Loncle C., Secq V., Garcia S., Lomberk G., Kroemer G., Urrutia R. Iovanna J.L. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. EMBO Mol. Med. Sep;4(9):964-79, 2012

Pommier R.M., Gout J., Vincent D.F., Cano C.E., Kaniewski B., Martel S., Rodriguez J., Fourel G., Valcourt U., Marie J.C., Iovanna J.L., Bartholin L. The human NUPR1/P8 gene is transcriptionally activated by transforming growth factor β via the SMAD signalling pathway. Biochem. J. Jul 15;445(2):285-93, 2012

Zerlanko B.J., Bartholin L., Wotton D. Premature senescence and increased TGFβ signaling in the absence of Tgif1. PLoS ONE 7(4):e35460. Epub 2012 Apr 13., 2012

Vincent D.F., Gout J., Chuvin N., Arfi V., Pommier R.M., Bertolino P., Jonckheere N., Ripoche D., Kaniewski B., Martel S., Langlois J.B., Goddard-Léon S., Colombe A., Janier M., Van Seuningen I., Valcourt U., Treilleux I., Dubus P., Bardeesy N., Bartholin L. TIF1γ and SMAD4 act in Separate Pathways to Suppress Kras-driven Pancreatic Tumorigenesis.  Am. J. Pathol. Jun;180(6):2214-21. Epub 2012 Mar 3, 2012

Vincent D., Kaniewski B., Powers S., Havenar-Daughton C., Marie J.C., Wotton D. Bartholin L. Allele in LSL-TβRICA Transgenic mice. Genesis Sep;48(9):559-62, 2010

Vincent D.F., Yan K.P., Treilleux I., Gay F., Arfi V., Kaniewski B., Marie J.C., Lepinasse F., Martel S.,  Goddard-Léon S., Iovanna J.L., Dubus P., Garcia S.,  Puisieux A., Rimokh R., Bardeesy N., Scoazec J.Y., Losson R., Bartholin L. Inactivation of TIF1γ Cooperates with KrasG12D to Induce Cystic Tumors of the Pancreas. PLoS Genet. Jul;5(7):e1000575. Epub 2009 Jul 24, 2009

Doisne J.M.#, Bartholin L. #, Yan K., Garcia C.N., Duarte N., Le Luduec J.B., Martel S., Horvat B.,  Vincent D.F., Cyprian F., Rimokh R., Losson R., Benlagha K., Marie J.C. iNKT Cell-development is Orchestrated by Different Branches of TGFβ Signaling. J. Exp. Med. Jun 8;206(6):1365-78. Epub 2009 May 18, 2009 #equal contribution

Bartholin L. *, Cyprian F.S., Vincent D.F., Garcia C.N., Martel S., Horvat B., Berthet C., Goddard-Léon S., Treilleux I., Rimokh R., Marie J.C. Generation of mice with conditionally activated transforming growth factor beta signaling through the TbetaRI/ALK5 receptor. Genesis Dec;46(12):724-31, 2008 *corresponding author

Bartholin L., Melhuish T.A.,. Powers S.E., Goddard-Léon S., Treilleux I., Sutherland A.E., Wotton D. Maternal Tgif is required for vascularization of the embryonic placenta. Dev. Biol. Jul 15;319(2):285-97, 2008

Razanajaona D., Joguet S., Ay A.S., Treilleux I., Goddard-Leon S., Bartholin L., Rimokh R. Silencing of FLRG, an Antagonist of Activin, Inhibits Human Breast Tumor Cell Growth. Cancer Res. Aug 1;67(15):7223-9, 2007

Forissier S., Razanajaona D., Ay A.S., Martel S., Bartholin L., Rimokh R. AF10 dependent transcription is enhanced by its interaction with FLRG. Biol. Cell  Oct;99(10):563-71, 2007

Bartholin L., Guindon S., Martel S., Corbo L., Rimokh R. Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene May 15;393(1-2):153-62, 2007

El-Jaick K.B., Powers S.E., Bartholin L., Myers K.R., Hahn J., Orioli I.M., Ouspenskaia M., Lacbawan F., Roessler E., Wotton D., Muenke M. Functional analysis of mutations in TGIF associated with holoprosencephaly. Mol. Genet. Metab. Jan;90(1):97-111, 2007

Bartholin L., Wessner L., Chirgwin J.M., Guise T.A. Transcriptional activation of hCCN1/Cyr61 gene by TGFβ. Cancer Lett.  Feb 8;246(1-2):230-236, 2007

Bartholin L., Powers S.E., Melhuish T.A., Lasse S., Weinstein M. and Wotton D. TGIF inhibits retinoid signaling.  Mol. Cell. Biol. Feb;26(3):990-1001.26, 2006

Maguer-Satta V., Forissier S., Bartholin L., Martel S., Jeanpierre S., Bachelard E., Rimokh. A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin. Exp. Cell Res. Feb 15;312(4):434-42, 2006

Bartholin L., Destaing O., Forissier S., Martel S., Maguer-Satta V., Jurdic P., Rimokh R. FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation. Biol. Cell Jul;97(7):577-88, 2005

Baseggio L., Bartholin L., Chantome A,. Charlot C., Rimokh R., Salles G. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. Eur. J. Immunogenet. Feb;31(1):15-9, 2004

Hyman C.A., Bartholin L., Newfeld S.J., Wotton D. Drosophila TGIF proteins are transcriptional activators. Mol. Cell. Biol. Dec;23(24):9262-74, 2003

Maguer-Satta V.#, Bartholin L.#, Jeanpierre S., Ffrench M.,  Magaud J.P., Rimokh R. Regulation of human erythropoiesis by Activin A, BMP2 and BMP4, two members of the TGFbeta family. Exp. Cell Res. Jan 15;282(2):110-20, 2003 #equal contribution
 
Hayette S., Tigaud I., Maguer-Satta V., Bartholin L., Thomas X., Charrin C., Gadoux, M., Magaud J.P., Rimokh R. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood Jun 15;99(12):4647-9, 2002

Bartholin L., Maguer-Satta V., Hayette S., Martel S., Gadoux M., Corbo L., Magaud J.P., Rimokh R. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function.  Oncogene Mar 28;21(14):2227-35, 2002

Bartholin L., Maguer-Satta V., Hayette S., Martel S., Gadoux M., Bertrand S., Corbo L., Lamadon C., Morera A.M., Magaud J.P., Rimokh R. FLRG, an activin-binding protein, is a new target of TGFbeta transcription activation through Smad proteins. Oncogene Sep 6;20(39):5409-19, 2001

Maguer-Satta V., Bartholin L., Jeanpierre S., Gadoux M., Bertrand S., Martel S., Magaud J.P., Rimokh R. Expression of FLRG, a novel activin A ligand, is regulated by TGFbeta and during hematopoiesis. Exp. Hematol. Mar;29(3):301-8, 2001

Birot A.M.,  Duret L., Bartholin L., Santalucia B., Tigaud I.,  Magaud J.P., Rouault J.P. Identification and molecular analysis of BANP. Gene Aug 8;253(2):189-96, 2000

Revues générales/Chapitres d'ouvrages spécialisés

1-Principe D.R., Doll J.A., Bauer J., Jung B., Munshi H.G., Bartholin L., Pasche B., Lee C., Grippo P.J., “TGFb: Duality of function between tumor prevention and carcinogenesis”, JNCI, Sous presse

2-Valcourt U., Carthy J., Okita Y., Alcaraz L., Kato M., Thuault S., Bartholin L., Moustakas A. Comprehensive chapter in special volume on “TGF-beta Signaling for Methods in Molecular Biology” for Methods in Molecular Biology (Chapter title: “Analysis of epithelial-mesenchymal transition induced by transforming growth factor β”). Edited by Feng X.H, Humana Press, Springer publishing group, Sous presse

3-Valcourt U., Pommier R., Vincent D.F., Bartholin L. Culture primaire de cellules pancréatiques exocrines de souris : un outil indispensable pour la compréhension de l’étiologie de la carcinogenèse pancréatique. Ouvrage: Culture de cellules animales (in French). Barlovatz-Meimon G., Guillouzo C., Ronot X. 3ème édition, Ed. Lavoisier, Sous presse

4- Bartholin L., Vincent D.F., Valcourt U. Comprehensive chapter in special volume on "TGF-beta in human disease" (Chapter title: “TGF-beta as tumor suppressor: in vitro mechanistic aspects of growth inhibition"). Edited by Moustakas A. and Miyazawa K. Springer Special Research Volumes, p113-138, 2013

5-Valcourt U., Vincent D., Bartholin L. Comprehensive chapter in special volume on "TGF-beta in human disease" (Chapter title: “TGF-beta as tumor suppressor: Lessons from mouse models”). Edited by Moustakas A. and Miyazawa K. Springer Special Research Volumes, p139-168, 2013

6-Bartholin L. Comprehensive chapter in “Mouse Models and Mesenchymal Targeting” book. (Chapter title “Pancreatic Cancer and the Tumor Microenvironment: Mesenchyme’s role in Pancreatic Carcinogenesis”). Edited by Paul J. Grippo (Northwestern University, Chicago, USA). Research Signpost Ed, 2012

7-Bartholin L. and Guise TyA. Comprehensive chapter in “TGF-beta in Cancer Therapy”, Beverly Teicher’s Methods in Molecular Biology series on “Cancer Drug Discovery and Development”. (Chapter title “Role of TGFb in osteolytic bone lesions”). Edited by Sonia B. Jakowlew (NIH, Bethesda, USA). Humana Press Book and Journal, Vol II “Cancer Treatment and Therapy”, 95-123, 2008

Publications réalisées dans le cadre de collaborations

Larrieu D, Brunet M, Vargas C, Hanoun N, Ligat L, Dagnon L, Lulka H, Pommier RM, Selves J, Jády BE, Bartholin L, Cordelier P, Dufresne M, Torrisani J. The E3 ubiquitin ligase TRIP12 participates in cell cycle progression and chromosome stability. Sci Rep. 2020 Jan 21;10(1):789. doi: 10.1038/s41598-020-57762-9.

 

Hilmi M., Rousseau B., Cohen R., Vienot A., Vernerey D., Bartholin L., Blanc-Durand F., Louvet C., Turpin A., Neuzillet C. [A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research]. Bull Cancer. 2019 Apr 12. pii: S0007-4551(19)30148-1. doi: 10.1016/j.bulcan.2019.02.009. [Epub ahead of print]

 

Hirai T., Zenke Y., Yang Y, Bartholin L., Beura L.K., Masopust D. and Kaplan D.H. Keratinocyte-Mediated Activation of the Cytokine TGF-β Maintains Skin Recirculating Memory CD8+ T Cells. Immunity. 2019 Mar 23. pii: S1074-7613(19)30092-5. doi: 10.1016/j.immuni.2019.03.002. [Epub ahead of print].


Ni N., Gao Y., Fang X., Melgar M., Vincent D.F., Lydon J.P., Bartholin L., Li Q. Glandular defects in the mouse uterus with sustained activation of TGF-beta signaling is associated with altered differentiation of endometrial stromal cells and formation of stromal compartment. PLoS One. 2018 Dec 14;13(12):e0209417. doi: 10.1371/journal.pone.0209417.

 

Barhli A., Cros J., Bartholin L., Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig. Liver. Dis. 2018 Oct;50(10):979-990. doi: 10.1016/j.dld.2018.08.009. Epub 2018 Aug 20. Review.

 

Hilmi M.*, Bartholin L.*, Neuzillet C.*. Immune therapies in PDAC: where are we now? World Journal of Gastroenterology *These authors have equally contributed to this work. 2018 May 28;24(20):2137-2151. Review.

 

Bird T.G., Ridgway R.A., Boulter L., Vincent D.F., Lopez-Guadamillas E., Lu W.Y., Jamieson T., Govaere O., Ferreira-Gonzalez S., Cole A.M., Hay T., Simpson K.J., Clarke M., Rocha A.S., Sprangers J., Nibbs R.J.B, Van Rooijen N., Bartholin L., Iredale J.P., Clarke A.R., Serrano M., Roskams T.A., Sansom O.J., Forbes S.J. TGFβ inhibition restores a regenerative response in acute liver injury via suppression of paracrine growth arrest with features of senescence. Sci Transl Med. 2018 Aug 15;10(454).

 

Fang X., Ni N., Gao Y., Vincent D.F., Bartholin L., Li Q. A Novel Mouse Model of Testicular Granulosa Cell Tumors. Mol. Human Reprod 2018 May 21. doi: 10.1093/molehr/gay023

 

Gao Y., Fang X., Vincent D.F., Threadgill D.W., Bartholin L., Li Q. Disruption of postnatal folliculogenesis and development of ovarian tumor in a mouse model with aberrant transforming growth factor beta signaling. Reprod Biol Endocrinol. 2017 Dec 8;15(1):94. doi: 10.1186/s12958-017-0312-z.

 

Gao Y., Souza-Fonseca-Guimaraes F., Bald T., Ng S.S., Young A., Ngiow S.F., Rautela J., Straube J., Waddell N., Blake S.J., Yan J., Bartholin L., Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017 Jul 31. doi: 10.1038/ni.3800. [Epub ahead of print]


Gao Y., Vincent D.F., Davis A.J., Sansom O.J., Bartholin L., and Li L. Constitutively Active Transforming Growth Factor β Receptor 1 in the Mouse Ovary Promotes Tumorigenesis.  Oncotarget 2016 Jun 17 [Epub ahead of print].

 

Viant C., Rankin L.C., Girard-Madoux M.J.H., Seillet C., Shi W., Smyth M.J., Bartholin L., Walzer T., Huntington ND, Vivier E, Belz GT. Transforming growth factor-β and Notch ligands act as opposing environmental cues in the plasticity of type 3 innate lymphoid cells Cell Signaling 2016 May 3;9(426).

 

Le Calvé B., Griveau A., Vindrieux D., Maréchal R., Wiel C., Svrcek M., Gout J., Azzi L., Payen L., Cros J., de la Fouchardière C., Dubus P., Guitton J., Bartholin L., Bachet J.B., Bernard D. Lysyl oxidase activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Oncotarget 2016 May 31;7(22):32100-12.

 

Thakur A., Nigri J., Lac S., Leca J., Bressy C., Berthezene P., Bartholin L., Chan P., Calvo E., Iovanna J.L., Vasseur S., Guillaumond F., Tomasini R. TAp73 Loss favors Smad-independent TGFβ signaling that drives EMT in pancreatic ductal adenocarcinoma Cell Death & Differentiation 2016 Aug;23(8):1358-70.

 

Viel S., Marçais A., Souza-Fonseca Guimaraes F., Loftus R., Rabilloud J., Grau M., Degouve S., Djebali S., Sanlaville A., Bienvenu J., Marie J., Caux C., Marvel J., Huntington N., Bartholin L., Finlay D., Smyth M.J., Walzer T. TGFβ inhibits NK cell activation and cytotoxicity through repression of the mTOR pathway. Cell Signaling 2016 Feb 16;9(415).


Valcourt U, Carthy J, Okita Y, Alcaraz L, Kato M, Thuault S, Bartholin L, Moustakas A. Analysis of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor β. Methods Mol Biol. 2016;1344:147-81. doi: 10.1007/978-1-4939-2966-5_9.


Mohammed J., Bobr A., Astry B., Chicoine B., Kashem S., Igyártó B., Matte C., Bartholin L., Kaplan A., Sheppard D., Bridges A., Shlomchik W., Beura L., Thompson E., Masopust D., Welty N., Wijeyesinghe S., &Kaplan D.H.  "Stromal cells control epithelial residence of DC and memory T cells by regulated activation of TGF-β" Nature Immunol. 2016 Apr;17(4):414-21.


Gao Y., Duran S., Lydon J.P., DeMayo F.J., Burghardt R.C., Bayless K.J., Bartholin L., Li Q. Constitutive activation of transforming growth factor Beta receptor 1 in the mouse uterus impairs uterine morphology and function. 2015 Biol. Reprod. Feb;92(2):34


Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Dusetti N, Bartholin L, Urrutia R, Iovanna JL. Gut. 2014; 63(6): 984-95.


Principe D.R., Doll J.A., Bauer J., Jung B., Munshi H.G., Bartholin L., Pasche B., Lee C., Grippo P.J., “TGFb: Duality of function between tumor prevention and carcinogenesis”. 2014 J. Natl. Cancer Inst., Feb 1;106(2):djt369. Review.

 

Wiel C, Augert A, vincent DF, Gitenay D, Vindrieux D, Le Calvé B, Arfi V, Lallet-Daher H, Reynaud C, Treilleux I, Bartholin L, Lelievre E, Bernard D. Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis. 2013; Oct 10 ; 4 e855.

 

Ripoche D, Gout J, Pommier RM, Jaafar R, Zhang CX, Bartholin L, Bertolino P. Generation of a conditional mouse model to target Acvr1b disruption in adult tissues. Genesis. 2013; 51(2): 120-7.


Cano CE, Sandí MJ, Hamidi T, Calvo EL, Turrini O, Bartholin L, Loncle C, Secq V, Garcia S, Lomberk G, Kroemer G, Urrutia R, Iovanna JL. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. EMBO Mol Med. 2012 Sep;4(9):964-79. doi: 10.1002/emmm.201201255. Epub 2012 Jul 23.

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :